Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial
Pagsberg A, Jeppesen P, Klauber DG, et al.
Lancet Psychiatry 6 June 2017. DOI: http://dx.doi.org/10.1016/S2215-0366(17)30166-9
This rare double-blind, placebo-controlled head to head trial of antipsychotic medications quetiapine ER and aripiprazole in 12-17 year olds with early-onset psychosis showed no significant difference in effectiveness between these medications. There were some differences in side effects though, with quetiapine ER being associated with more metabolic side-effects and aripiprazole being associated with more akathisia and (unexpectedly) more sedation. The authors recommend continuing to look at side-effect profiles when deciding which antipsychotic to use.
http://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(17)30166-9/abstract